204 related articles for article (PubMed ID: 32131709)
21. Medullary Thyroid Carcinoma in MEN2A: ATA Moderate- or High-Risk RET Mutations Do Not Predict Disease Aggressiveness.
Voss RK; Feng L; Lee JE; Perrier ND; Graham PH; Hyde SM; Nieves-Munoz F; Cabanillas ME; Waguespack SG; Cote GJ; Gagel RF; Grubbs EG
J Clin Endocrinol Metab; 2017 Aug; 102(8):2807-2813. PubMed ID: 28609830
[TBL] [Abstract][Full Text] [Related]
22. Risk Factors Associated With Reoperation and Disease-Specific Mortality in Patients With Medullary Thyroid Carcinoma.
Kuo EJ; Sho S; Li N; Zanocco KA; Yeh MW; Livhits MJ
JAMA Surg; 2018 Jan; 153(1):52-59. PubMed ID: 28973144
[TBL] [Abstract][Full Text] [Related]
23. The dilemma of metastatic medullary thyroid carcinoma: when to start systemic treatment.
Siano M; Alfieri S; Granata R; Calareso G; Orlandi E; Bergamini C; Locati LD
Tumori; 2019 Dec; 105(6):NP28-NP31. PubMed ID: 30782103
[TBL] [Abstract][Full Text] [Related]
24. Anti-carcinoembryonic antigen antibodies versus somatostatin analogs in the detection of metastatic medullary thyroid carcinoma: are carcinoembryonic antigen and somatostatin receptor expression prognostic factors?
Behr TM; Gratz S; Markus PM; Dunn RM; Hüfner M; Schauer A; Fischer M; Munz DL; Becker H; Becker W
Cancer; 1997 Dec; 80(12 Suppl):2436-57. PubMed ID: 9406695
[TBL] [Abstract][Full Text] [Related]
25. Early changes in carcinoembryonic antigen but not in calcitonin levels are correlated with the progression-free survival in medullary thyroid carcinoma patients treated with cytotoxic chemotherapy.
Hajje G; Borget I; Leboulleux S; Chougnet C; Al Ghuzlan A; Mirghani H; Caramella C; Hartl D; Schlumberger M; Baudin E
Eur J Endocrinol; 2013 Feb; 168(2):113-8. PubMed ID: 23093698
[TBL] [Abstract][Full Text] [Related]
26. ¹⁸F-FDG PET predicts survival after pretargeted radioimmunotherapy in patients with progressive metastatic medullary thyroid carcinoma.
Salaun PY; Campion L; Ansquer C; Frampas E; Mathieu C; Robin P; Bournaud C; Vuillez JP; Taieb D; Rousseau C; Drui D; Mirallié E; Borson-Chazot F; Goldenberg DM; Chatal JF; Barbet J; Kraeber-Bodéré F
Eur J Nucl Med Mol Imaging; 2014 Aug; 41(8):1501-10. PubMed ID: 24806110
[TBL] [Abstract][Full Text] [Related]
27. Imaging medullary thyroid carcinoma with persistent elevated calcitonin levels.
Giraudet AL; Vanel D; Leboulleux S; Aupérin A; Dromain C; Chami L; Ny Tovo N; Lumbroso J; Lassau N; Bonniaud G; Hartl D; Travagli JP; Baudin E; Schlumberger M
J Clin Endocrinol Metab; 2007 Nov; 92(11):4185-90. PubMed ID: 17726071
[TBL] [Abstract][Full Text] [Related]
28. Clinical relevance of 18F-FDG PET and 18F-DOPA PET in recurrent medullary thyroid carcinoma.
Verbeek HH; Plukker JT; Koopmans KP; de Groot JW; Hofstra RM; Muller Kobold AC; van der Horst-Schrivers AN; Brouwers AH; Links TP
J Nucl Med; 2012 Dec; 53(12):1863-71. PubMed ID: 23081996
[TBL] [Abstract][Full Text] [Related]
29. Progression of medullary thyroid carcinoma: assessment with calcitonin and carcinoembryonic antigen doubling times.
Laure Giraudet A; Al Ghulzan A; Aupérin A; Leboulleux S; Chehboun A; Troalen F; Dromain C; Lumbroso J; Baudin E; Schlumberger M
Eur J Endocrinol; 2008 Feb; 158(2):239-46. PubMed ID: 18230832
[TBL] [Abstract][Full Text] [Related]
30. Clinical and pathological analysis of 19 cases of medullary thyroid carcinoma without an increase in calcitonin.
Zhou Q; Yue S; Cheng Y; Jin J; Xu H
Exp Toxicol Pathol; 2017 Oct; 69(8):575-579. PubMed ID: 28552629
[TBL] [Abstract][Full Text] [Related]
31. Prognostic impact of serum calcitonin and carcinoembryonic antigen doubling-times in patients with medullary thyroid carcinoma.
Barbet J; Campion L; Kraeber-Bodéré F; Chatal JF;
J Clin Endocrinol Metab; 2005 Nov; 90(11):6077-84. PubMed ID: 16091497
[TBL] [Abstract][Full Text] [Related]
32. Medullary Thyroid Carcinoma: Survival Analysis and Evaluation of Mutation-Specific Immunohistochemistry in Detection of Sporadic Disease.
Jayakody S; Reagh J; Bullock M; Aniss A; Clifton-Bligh R; Learoyd D; Robinson B; Delbridge L; Sidhu S; Gill AJ; Sywak M
World J Surg; 2018 May; 42(5):1432-1439. PubMed ID: 29484475
[TBL] [Abstract][Full Text] [Related]
33. Surgical strategy for the treatment of sporadic medullary thyroid carcinoma: our experience.
Lupone G; Antonino A; Rosato A; Zenone P; Iervolino EM; Grillo M; De Palma M
G Chir; 2012; 33(11-12):395-9. PubMed ID: 23140924
[TBL] [Abstract][Full Text] [Related]
34. Complementary roles of 18F-DOPA PET/CT and 18F-FDG PET/CT in medullary thyroid cancer.
Kauhanen S; Schalin-Jäntti C; Seppänen M; Kajander S; Virtanen S; Schildt J; Lisinen I; Ahonen A; Heiskanen I; Väisänen M; Arola J; Korsoff P; Ebeling T; Sane T; Minn H; Välimäki MJ; Nuutila P
J Nucl Med; 2011 Dec; 52(12):1855-63. PubMed ID: 22052128
[TBL] [Abstract][Full Text] [Related]
35. Outcome of Patients with Locally Advanced Metastatic Medullary Thyroid Cancer and Induction Therapy with Tyrosine Kinase Inhibitors in Slovenia.
Grasic Kuhar C; Lozar T; Besic N; Music Marolt M
Adv Ther; 2021 Dec; 38(12):5684-5699. PubMed ID: 34674146
[TBL] [Abstract][Full Text] [Related]
36. The role of hepatic trans-arterial chemoembolization in metastatic medullary thyroid carcinoma: a specialist center experience and review of the literature.
Grozinsky-Glasberg S; Bloom AI; Lev-Cohain N; Klimov A; Besiso H; Gross DJ
Eur J Endocrinol; 2017 Apr; 176(4):463-470. PubMed ID: 28100632
[TBL] [Abstract][Full Text] [Related]
37. International Medullary Thyroid Carcinoma Grading System: A Validated Grading System for Medullary Thyroid Carcinoma.
Xu B; Fuchs TL; Ahmadi S; Alghamdi M; Alzumaili B; Bani MA; Baudin E; Chou A; De Leo A; Fagin JA; Ganly I; Glover A; Hartl D; Kanaan C; Khneisser P; Najdawi F; Nigam A; Papachristos A; Repaci A; Spanheimer PM; Solaroli E; Untch BR; Barletta JA; Tallini G; Al Ghuzlan A; Gill AJ; Ghossein RA
J Clin Oncol; 2022 Jan; 40(1):96-104. PubMed ID: 34731032
[TBL] [Abstract][Full Text] [Related]
38.
Souteiro P; Gouveia P; Ferreira G; Belo S; Costa C; Carvalho D; Duarte H; Sampaio IL
Endocrine; 2019 May; 64(2):322-329. PubMed ID: 30684230
[TBL] [Abstract][Full Text] [Related]
39. Trends in the Diagnosis and Treatment of Patients with Medullary Thyroid Carcinoma in Korea.
Ahn HY; Chae JE; Moon H; Noh J; Park YJ; Kim SG
Endocrinol Metab (Seoul); 2020 Dec; 35(4):811-819. PubMed ID: 33212545
[TBL] [Abstract][Full Text] [Related]
40. Long-Term Outcome After Surgery for Medullary Thyroid Carcinoma: A Single-Center Experience.
Torresan F; Cavedon E; Mian C; Iacobone M
World J Surg; 2018 Feb; 42(2):367-375. PubMed ID: 29134313
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
